Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease (Q37845821)

24 August 2017

1 reference

title

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease (English)

1 reference

24 August 2017

0 references

0 references

0 references

2

Harald Hampel

1 reference

24 August 2017

David Prvulovic

1

1 reference

24 August 2017

publication date

23 February 2011

1 reference

Clinical Chemistry and Laboratory Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

49

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

367-374

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

24 August 2017

1 reference

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Aspects of beta-amyloid as a biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

A default mode of brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Disruption of functional connectivity in clinically normal older adults harboring amyloid burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid deposition is associated with impaired default network function in older persons without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Selective changes of resting-state networks in individuals at risk for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

White matter microstructure underlying default mode network connectivity in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Proline-directed and non-proline-directed phosphorylation of PHF-tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Association of GSK3B with Alzheimer disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.087

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.087

1 reference

24 August 2017

1 reference